Arcturus Therapeutics Holdings Inc.
ARCT
$12.91
$0.020.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 152.31M | 160.40M | 163.87M | 124.53M | 166.80M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 152.31M | 160.40M | 163.87M | 124.53M | 166.80M |
| Cost of Revenue | 140.07M | 132.91M | 144.85M | 144.21M | 143.21M |
| Gross Profit | 12.25M | 27.49M | 19.02M | -19.69M | 23.59M |
| SG&A Expenses | 52.82M | 52.95M | 53.05M | 53.96M | 52.87M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 247.18M | 240.15M | 252.19M | 247.10M | 245.00M |
| Operating Income | -94.87M | -79.75M | -88.32M | -122.57M | -78.21M |
| Income Before Tax | -80.94M | -62.38M | -70.59M | -105.20M | -27.89M |
| Income Tax Expenses | -3.00K | 263.00K | 1.37M | 2.10M | 1.84M |
| Earnings from Continuing Operations | -80.94 | -62.64 | -71.96 | -107.30 | -29.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.94M | -62.64M | -71.96M | -107.30M | -29.73M |
| EBIT | -94.87M | -79.75M | -88.32M | -122.57M | -78.21M |
| EBITDA | -91.33M | -76.21M | -84.87M | -119.29M | -75.25M |
| EPS Basic | -3.00 | -2.33 | -2.69 | -4.03 | -1.12 |
| Normalized Basic EPS | -1.86 | -1.43 | -1.63 | -2.45 | -1.45 |
| EPS Diluted | -3.01 | -2.34 | -2.69 | -4.03 | -1.16 |
| Normalized Diluted EPS | -1.86 | -1.43 | -1.63 | -2.45 | -1.46 |
| Average Basic Shares Outstanding | 107.91M | 107.54M | 107.05M | 106.64M | 106.32M |
| Average Diluted Shares Outstanding | 107.91M | 107.54M | 107.05M | 106.64M | 106.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |